Profile cover photo
Profile photo
MultiplexDX
3 followers -
MultiplexDX is one of the most innovative biotech corporation founded to bring its revolutionary Multiplex™ technologies on the mark
MultiplexDX is one of the most innovative biotech corporation founded to bring its revolutionary Multiplex™ technologies on the mark

3 followers
About
Communities and Collections
Posts

Post has attachment
MultiplexDX is the first company from the CEE region to become an honorable member of the Oslo Cancer Cluster (OCC). The cluster’s main mission is to improve cancer patients’ lives by accelerating the development of new diagnostics and treatment.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“Being a member of OCC means to get powerful support for all innovation phases from early-stage development until commercialization. The cluster’s members represent the entire oncology value chain making it an ideal environment for launching new products! We are very excited to be part of this great alliance and look forward to sharing our experience as well as developing new opportunities for our innovations!”

Also, OCC membership facilitates the participation in international conferences, helps its members to showcase their R&D activities at professional forums and meetings, establishes direct connections between cluster members and relevant international partners, and initiates meetings with public authorities in order to influence the health authorities. MultiplexDX plans to expand its new business team responsible for the interactions with OCC and that will help to facilitate Multiplex9+ market entry and to secure future companion DX projects.

Read more http://bit.ly/2FjsxwS
Add a comment...

Post has attachment

MultiplexDX Gave a Pitch at Innovative Enterprise Vienna 2018!
Only six 'Seal of Excellence' startups out of 300 were chosen for the open deal session and MultiplexDX was among them! The company leader (Dr. Pavol Cekan) and the main investor (Michal Nespor from Crowdberry) were given the eight-minute pitching time to present the company and answer the questions. The open deal session was also broadcasted online and seen by hundreds of investors worldwide. Immediately after the pitch Norwegian and Italian VC funds contacted MultiplexDX with potential interest to invest.

Innovative Enterprise Vienna, a joint event of the European Commission and the Austrian EU Council Presidency, primarily aims to support highly innovative start-up and scale-up enterprises in their successful new markets’ entry. This year’s conference specifically contributed to gaining better insight into the requirements of the present European financing opportunities for innovations (InnovFin, Horizon 2020, Eurostars, EFSI) and future ones (Horizon Europe, Invest EU). Also, the organizers chose the best “Seal of Excellence” projects to show parallel finance pitching sessions in practice.‍
http://bit.ly/2QYnxDV
Photo
Add a comment...

Post has attachment
MultiplexDX Wins CESAwards’ "Best Social Impact Startup" in the CEE Region

We are happy to announce one more award for MultiplexDX! Less than one month after receiving three Central European Startup Awards (CESAwards) during the national round in Slovakia, MultiplexDX won the regional round in the Best Social Impact Startup category. The CESAwards’ regional round was held in Warsaw, Poland, on the 24th of October, 2018. This year, the 5th for the CESAwards, its winners were selected from over 3,500 applicants from 10 CEE countries, and more than 40,000 individual public voters supported the finalists during the selection process. The Best Social Impact Startup category is designated for innovative companies which develop and implement solutions to social, cultural, or environmental issues, and have shown the greatest progress over the last year.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:

“It was such a pleasant surprise and a big honor for us to be chosen as the ‘Best Social Impact Startup’ from 10 Central and Eastern European countries. We’re actually the first company from Slovakia to win any award in the regional CESAwards round. Now we’ve earned entry to the Global Grand Finale in Guangzhou, China. Let’s keep our fingers crossed, as the best startups from 60 countries worldwide will compete in this final round!”

Dr. Cekan also mentioned that such competitions are always a great chance to see what impression the company makes and how competitive it is in general. Read more - https://www.multiplexdx.com/post/multiplexdx-wins-cesawards-best-social-impact-startup-in-the-cee-region
Add a comment...

Post has attachment
MultiplexDX Applies for Patent to Secure its Revolutionary Technology
Last week, MultiplexDX submitted a European patent application (EP 18198751.2) covering its Multiplex9+ diagnostic method. The innovation got the official title “Method for diagnosing diseases using multiplex fluorescence and sequencing” with the designated inventor listed as Dr. Pavol Cekan, Founder and CEO of MultiplexDX. The application protects both the 9th and 25th biomarkers’ diagnostic barcodes for breast cancer, which are used in Multiplex9+. It also protects the multiplexed combination of RNA visualization and sequencing, and all innovations used in MultiplexDX® RNA FISH and RNAseq technologies. Now the application is filed in two patent offices in Europe and Luxemburg, and MultiplexDX is going to convert it into a national patent application in the USA, Canada, Japan, and China.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“This was an important step, actually an indispensable part of our business strategy, to secure the innovations. Nowadays, those companies who continue to promote and advance innovations should champion strong IP rights. MultiplexDX is among them! With a mission to become a policymaker in the market of biotech innovations, we are definitely on the right track!”
Reliable early-stage diagnostics is of the utmost importance and is the key to successful therapy. Thus, securing the patent for Multiplex9+ is so important. Introducing it to the market as soon as possible will save thousands of people from suffering and dying from cancer misdiagnosis all over the world.
The application was prepared and submitted in collaboration with the professional and award-winning German law firm Schiweck Weinzierl Koch (SWK).
https://www.multiplexdx.com/post/multiplexdx-applies-for-a-patent-to-secure-its-revolutionary-technology
Add a comment...

Post has attachment
MultiplexDX Wins Three Central European Startup Awards
MultiplexDX continues its streak of award-winning in 2018, having already been labeled “the emerging biotechnology star of Central Europe.” Last week, the company won 3 CESAwards: Best Social Impact of the Year, Best Biotech Startup, and Founder of the Year (Pavol Cekan). The Central European Startup Awards—the Central and Eastern Europe division of the Global Startup Awards—aims to find, highlight, and showcase the future-shapers of Poland, Czechia, Slovakia, Hungary, Austria, Serbia, Slovenia, Croatia, Romania, and Bulgaria. This year, the best and the most innovative startups competed in 14 categories, as well as investors, co-working centers and incubators. MultiplexDX was definitely one of the favorites.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“Getting three awards at once was a great surprise for us! On behalf of the MultiplexDX team, I'd like to thank CESAwards' experts for such a glowing evaluation of our project. We are very excited to represent Slovakia in the regional round in Warsaw, and to tell the world more about our innovations in cancer diagnostics!”
https://www.multiplexdx.com/post/multiplexdx-wins-three-central-european-startup-awards
Add a comment...

Post has attachment
MultiplexDX Receives €1,2 Million in Investments
Last week, MultiplexDX, led by renowned scientist Dr. Pavol Cekan, received the largest investment in the Slovakian biotech industry. The company got 1,2 million euros from American Ronald Cook, several investors from the Crowdberry investment platform, as well as other angel investors, who all became co-owners of MultiplexDX. The company was founded two years ago with a vision to make its unique cancer diagnostics the worldwide standard. Thanks to its revolutionary technology, the proportion of well-established diagnoses could increase to 99 percent.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“Cordial thanks to Ronald Cook, the Crowdberry platform, Neulogy Ventures, our angel investors and many other amazing people who believe in us, our innovations and mission to eliminate cancer misdiagnosis! This second investment is an important milestone for the company. We're going to follow our current strategy, enhance our team, expand our corporate infrastructure (including building a cutting-edge laboratory in Slovakia), and boost marketing and sales.”
MultiplexDX holds many international awards, including the Slovak Startup Awards 2016, CESAwards Slovakia 2018, the JCI Creative Young Entrepreneur of 2018, the Biotech Standard of Excellence WebAward 2018, and a prestigious placement in the Health Hub Vienna program. The company has recently joined the “New Europe 100,” ranked by Google and The Financial Times, as the emerging biotechnology star of Eastern Europe. Read more - https://www.multiplexdx.com/post/multiplexdx-receives-eu1-2-million-in-investments
Add a comment...

Post has attachment
MultiplexDX Receives €176 000 Grant from the Slovak Ministry of Education
It is amazing how MultiplexDX is developing from a small startup into a truly influential company, capable of shaking up the old biotech market with its revolutionary innovations. Although it is less than 2 years since its founding, MultiplexDX has won more than 15 prestigious awards, grants, and coveted placements in special programs as well as significant media and investor attention. This pattern of success continued this summer when MultiplexDX received a €176 000 grant from the Ministry of Education of the Slovak Republic.

‍Dr. Peter Kilian, founder and COO of MultiplexDX, comments: "It was a very pleasant surprise for us to get this significant support from the government. We are proud to be chosen from more than 270 projects and very thankful for this great opportunity! With such a substantial support, both from the government and private investors from around the world, we will do our best to bring MultiplexDX innovations to the market as soon as possible and help thousands of people to beat cancer!"
https://www.multiplexdx.com/post/multiplexdx-receives-eu176-000-grant-from-the-slovak-ministry-of-education
Add a comment...

Post has attachment
MultiplexDX Selected to Join Health Hub Vienna, One of Europe’s Premiere Accelerators!
From more than 100 worldwide applicants, only 11 startups were selected for the second batch of Health Hub Vienna (HHV), a three-month intensive acceleration program. This batch is multinational, featuring participants from the USA, UK, Sweden, Israel, Belarus, Slovakia, Germany, and only 3 from Austria.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
"Health Hub Vienna is one of the top 3 accelerators in Europe. Of course, it's an amazing opportunity for us to participate in this program and meet the industry’s best experts, mentors, investors, advisors, etc. It's a unique chance to get a new insight, upgrade our business model, build a powerful network, and progress much more quickly!"
https://www.multiplexdx.com/post/multiplexdx-selected-to-join-health-hub-vienna-one-of-europes-premiere-accelerators
Add a comment...

Post has attachment
MultiplexDX wins Standard of Excellence Awards from the Web Marketing Association (WMA). Independent expert judges from around the world gave MultiplexDX official website the highest scores for the innovation, design, content, ease of use, interactivity, copywriting and technology.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:

We are innovative in everything! Be it our products, marketing strategy or web presence. We are lucky to have a team of really forward-thinking people who generate new approaches and find efficient ways how to hit the market. All our recent awards prove that we chose a right direction and underline the quality of the work we are doing.
https://www.multiplexdx.com/post/multiplexdx-wins-standard-of-excellence-awards-from-the-web-marketing-association-wma
PhotoPhotoPhoto
9/21/18
3 Photos - View album
Add a comment...

Post has attachment

We are happy to announce that MultiplexDX was awarded Horizon 2020 Seal of Excellence by the European Commission. In a highly competitive process, MultiplexDX received a prestigious Seal of Excellence from the European Commission managing Horizon 2020 program for research and innovation 2014-2020. An international panel of independent experts evaluated Multiplex9 as a high-quality project proposal recommended for funding. Multiplex9 is a revolutionary highly accurate cancer diagnostic test for assessment of both therapy response and personalized prognosis.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments: «For us, it's a great proof that our project, business plan, commercialization strategy and team are very innovative and bound to be successful! We're now on the last round of fundraising and soon going to proceed to our next stage of development.»
More importantly, this year MultiplexDX H2020 SME instrument phase 2 submission got the highest (above 4 threshold) score for impact, excellence and implementation. Such a high evaluation from the European Commission experts will significantly increase the company's chances to be awarded with € 2,8 mil. SME grant in the next round.
Photo
Add a comment...
Wait while more posts are being loaded